MedTrace Logo

Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.

NCT05228912 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1870

Last updated 2023-02-28

No results posted yet for this study

Summary

Background: Scarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-COV2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.

Methods: A multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers are being measured at baseline, 21-28 days after the first and second dose (when applicable), six months and a year of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models will be performed for the analyses.

Conditions

  • Vaccine Adverse Reaction
  • COVID-19
  • Vaccine Reaction

Interventions

DRUG

COVID-19 Vaccines

Each group will receive a complete scheme of the vaccine according to local government assignation

Sponsors & Collaborators

  • Universidad de Monterrey

    collaborator OTHER

  • Politecnico di Milano

    collaborator OTHER

  • Hospital de San Jose

    collaborator OTHER

  • Hospital Interzonal de Agudos San Juan Bautista

    collaborator OTHER

  • Federal University of Minas Gerais

    collaborator OTHER

  • Fundación San Francisco Javier

    collaborator UNKNOWN

  • Humanitas Research Hospital IRCCS, Rozzano-Milan

    collaborator OTHER

  • Hospital Clinica Nova

    lead OTHER

Principal Investigators

  • Maria Elena Romero-Ibarguengoitia, MD, MS, PHD · Hospital Clinica Nova de Monterrey

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-26
Primary Completion
2022-10-01
Completion
2022-10-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05228912 on ClinicalTrials.gov